

## PUBLICATIONS

Kaeser-Fröhlich A.: Are You Made for the Freelance Life? *interaktiv*, Volume 2, 2007.

Kaeser-Fröhlich A.: Glossary of Terms Used in Clinical Research. Caduceus, Winter 2003/2004.

Raßmann I., Thödtmann R., Mross M., Hüttmann A., Berdel W.E., Manegold C., Fiebig H.H., Kaeser-Fröhlich A., Burk K., Hanauske A.-R.: Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK 611 administered as intravenous short infusion. *Invest New Drugs* 1999; 16 (4):319-324.

Braess J., Kern W., Unterhalt M., Kaufmann C.C., Ramsauer B., Schüßler M., Kaeser-Fröhlich A., Hiddemann W., and Schleyer E.: Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantrone. *Ann Hematol* 1996 Oct; 73 (4):201-4.

Raßmann I., Schroedel H., Schilling T., Zucchetti M., Kaeser-Fröhlich A., Rastetter J., Hanauske A.-R.: Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days. *Invest New Drugs* 1996; 14(4):379-86.

Raßmann I., Schilling T., Mross K., Hüttmann A., Berdel W.E., Manegold C., Fiebig H.H., Kaeser-Fröhlich A., Burk K., Rastetter J., Hanauske A.-R.: Clinical phase I evaluation of NK611 administered once every 28 days. *Ann Oncol* 1996; 7 (Suppl. 1):101.

Pagani O., Zucchetti M., Sessa C., De Jong J., D'Incalci M., DeFusco M., Kaeser-Fröhlich A., Hanauske A.-R., Cavalli F.: Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. *Cancer Chemother Pharmacol* 1996; 38 (6):541-7.

Hanauske A.R., Wüster K.C., Lehmer A., Rotter M., Schneider P., Kaeser-Fröhlich A., Rastetter I., and Depenbrock H.: Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. *Eur J Cancer* 1995; Volume 31 (Suppl. 10):1677-81.

Rassman I., T. Schilling, H. Schroedel, Kaeser-Fröhlich A., Burk K., Rastetter R., and Hanauske A.-R.: Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK 611 using an oral daily administration schedule. *Eur J Cancer* 1995; Volume 31 (Suppl. 6): S27.

Heußner P., Schleyer E., Amadori S., Ganser A., Guilhot F., Hanauske A.R., Heil, G., Hiddemann W., Kolbe K., Selbach J., Stryckmans P., Willem ze R., Kaeser-Fröhlich A., Schüßler M., Burk K.; Freund M.: A Phase I/II trial of YNK01, an oral ara-C derivative in patients with AML, MDS and low-grade malignant NHL. *Onkologie* 1994; 17 (Suppl. 2):61 (Abstr).

Hanauske A.-R., Wüster K.C., Depenbrock H., Peter R., Block T., Vogelsang H., Rotter M., Burk K., Fröhlich A., Rastetter J.: Preclinical activity of NK-611, a new podophyllotoxin derivative, against clonogenic tumor cells. *Proc Amer Assoc Cancer Res* 1994; 35:2388.

Schilling T., Mross K., Berdel W.E., Manegold C., Fiebig H.H., Hüttmann A., Kaeser-Fröhlich A., Hanauske A.-R. for the Phase I Study Group of the AIO: Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611. *Ann Oncol* 1994;5 (Suppl. 5):193.

Zucchetti M., De Fusco M., Sessa C., Fröhlich A., Reichert S., D'Incalci M.: High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. *J Chromatogr B Biomed Appl.* 1994 Mar 18; 654(1):97-102.

Rogy S., Fröhlich A., Anderle K., Schoppmann A.: Factor VIII Inhibitors – Therapeutic Options. *Die Ellipse*, No. 19, June 1989.

Anderle K., Fröhlich A.: Review of studies with plasminogen concentrates and proposals for further therapeutic strategies with plasminogen concentrates. *Haemostasis* 1988; 18, Suppl.1:165-175.